GSK Shares Rise Pre-Market Following FDA Approval of Menveo Single-Vial Formulation

Gelonghui October 18th丨GlaxoSmithKline (GSK.US), which closed up nearly 2% yesterday, continued to rise 0.83% in pre-market trading on the U.S. stock market today, reaching $31.56. In terms of news, GlaxoSmithKline has expanded its R&D agreement with Tempus in the field of precision medicine. Additionally, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline's Menveo as a new single-vial formulation for the prevention of diseases caused by meningococcal serogroups A, C, Y, and W-135 in individuals aged 10 to 55.